Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04787471 · ClinicalTrials.gov registry record · Phase 2
Corneal Crosslinking for Treatment of Corneal Neovascularization
A Phase 2 study of Corneal Neovascularization, sponsored by Price Vision Group.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT04787471: Recruiting Phase 2 study of Corneal Neovascularization, sponsored by Price Vision Group.
NCT04787471 is a Phase 2 study of Corneal Neovascularization that is actively recruiting participants, run by Price Vision Group. The registered enrollment target is 62 participants, roughly in line with the 62-participant average among 3 other Corneal Neovascularization trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04787471, a Phase 2 study of Corneal Neovascularization, is actively recruiting participants, sponsored by Price Vision Group.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
Primary Outcome
the cornea will be photographed and morphometric image analysis software will be used to measure corneal neovascularization as a proportion of the total corneal area. The proportion measured at baseline will be compared with the proportion measured at 6 months after treatment.
Conditions Studied
Interventions
- COMBINATION_PRODUCT 30 minute photoactivation of riboflavin 0.1%
- COMBINATION_PRODUCT 10 minute photoactivation of riboflavin 0.1%
Study Locations (1)
Indiana
- Price Vision Group - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2021-05-03 |
| Est. Completion | 2026-09-15 |
| Phase | Phase 2 |
What NCT04787471 shows while recruiting
NCT04787471 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, roughly in line with the 62-participant average among 3 other Corneal Neovascularization trials with a reported enrollment target.
The record links to 1 condition, with Corneal Neovascularization appearing as the primary indexed condition, and to 2 interventions - of which 30 minute photoactivation of riboflavin 0.1% is the first listed.
NCT04787471 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT04787471 about?
NCT04787471 is a clinical study titled "Corneal Crosslinking for Treatment of Corneal Neovascularization". The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
What is the current status of trial NCT04787471?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2021-05-03. Estimated completion is 2026-09-15.
What conditions does trial NCT04787471 study?
This clinical trial studies the following conditions: Corneal Neovascularization.
What interventions are being tested in trial NCT04787471?
The interventions under investigation include: 30 minute photoactivation of riboflavin 0.1% (COMBINATION_PRODUCT), 10 minute photoactivation of riboflavin 0.1% (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04787471?
This trial is sponsored by Price Vision Group, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04787471 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Corneal Neovascularization
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
COMPLETED · Phase 1
-
Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization
COMPLETED · NA
-
Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI